Test de diagnostic rapide des infections à Clostridium difficile (impact médico-économique)

TOULOUSE3-BU Santé-Centrale (315552105) / SudocSudocFranceF

Bactéries multirésistantes dans l'environnement (recherche dans les effluents de la ville de Toulouse)

LIMOGES-BU Médecine pharmacie (870852108) / SudocLYON1-BU Santé (693882101) / SudocSudocFranceF

Légionelles et pseudomonas dans les biofilms en simulateurs de réseau alimentés en eau thermale

MONTPELLIER-BU Pharmacie (341722105) / SudocSudocFranceF

Relations entre amibes libres, légionelles et pseudomonas dans divers environnements techniques et en co-cultures

Ce travail traite des inter-relations entre Legionella pneumophila, Pseudomonas aeruginosa et les amibes libres en milieu hydrique. En effet, ces protozoaires pourraient être de véritables vecteurs bactériens voire amplificateurs. Il se greffe parallèlement un problème sanitaire puisque les légionelles ont l origine d épidémies dont le point de départ est un environnement hydrique contaminé. De plus, certaines amibes libres et P. aeruginosa ont aussi un pouvoir pathogène. Un état des lieux a donc été réalisé sur leur présence dans divers environnements techniques. Les amibes libres y sont très présentes et l on ne retrouve des légionelles qu en leur présence. Cette hypothèse a alors été étudiée in vitro en eau thermale préalablement stérilisée. Elle confirme que certains genres amibiens permettent la multiplication des légionelles à l inverse du genre Willaertia. Les P. aeruginosa quant à eux entraînent la lyse amibienne par synthèse de facteurs de virulence.MONTPELLIER-BU Pharmacie (341722105) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

Estimation et évolution comparée de l'assimilation nette de couverts de maïs (Zea mays L.), tournesol (Helianthus annuus L.) et soja (Glycine max (L.) Merrill), au cours de leurs cycles de développement

International audienc

qnrA in CTX-M-Producing Escherichia coli Isolates from France

By PCR, we screened for qnr genes 112 clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli collected from hospitals in France during 2004. For the first time, 7.7% of CTX-M-producing E. coli isolates presented a plasmid-mediated resistance to quinolones. All strains harbored a qnrA gene located on a sul1-type class 1 integron with similar structure to the In36 integron

Isolation on chocolate agar culture of Legionella pneumophila isolates from subcutaneous abscesses in an immunocompromised patient

Cutaneous infections due to Legionella species have rarely been reported (L. J. Padrnos, J. E. Blair, S. Kusne, D. J. DiCaudo, and J. R. Mikhael, Transpl Infect Dis 16:307-314, 2014; P. W. Lowry, R. J. Blankenship, W. Gridley, N. J. Troup, and L. S. Tompkins, N Engl J Med 324:109-113, 1991; M. K. Waldor, B. Wilson, and M. Swartz, Clin Infect Dis 16:51-53, 1993). Here we report the identification of Legionella pneumophila isolates, from subcutaneous abscesses in an immunocompromised patient, that grew in an unusual medium for Legionella bacteria

CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors.

In 2004, 65 CTX-M-producing Escherichia coli isolates were collected from infected patients in four French hospitals. The blaCTX-M-15 genes were predominant. Pulsed-field gel electrophoresis highlighted a clonal propagation of CTX-M-15-producing strains belonging to phylogenetic group B2, notably in the community. The main risk factors for acquiring these isolates were urinary tract infections or the presence of a urinary catheter in diabetic or renal failure patients

Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry

International audienceTropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease -modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease. Methods: We initiated a registry including patients with disease -modifying antirheumatic drugs -treated inflammatory rheumatic disease who were subsequently diagnosed with Tropheryma whipplei infection. We collected clinical, biological, treatment data of the inflammatory rheumatic disease, of Tropheryma whipplei infection, and impact of antibiotics on the evolution of inflammatory rheumatic disease. Results: Among 73 inflammatory rheumatic disease patients, disease-modifying antirheumatic drugs initiation triggered extra-articular manifestations in 27% and resulted in stabilisation (51%), worsening (34%), or improvement (15%) of inflammatory rheumatic disease. At the diagnosis of Tropheryma whipplei infection, all patients had rheumatological symptoms (mean age 58 years, median inflammatory rheumatic disease duration 79 months), 84% had extra-rheumatological manifestations, 93% had elevated C-reactive protein, and 86% had hypoalbuminemia. Treatment of Tropheryma whipplei infection consisted mainly of doxycycline plus hydroxychloroquine, leading to remission of Tropheryma whipplei infection in 79% of cases. Antibiotic treatment of Tropheryma whipplei infection was associated with remission of inflammatory rheumatic disease in 93% of cases and enabled disease-modifying antirheumatic drugs and glucocorticoid discontinuation in most cases. Conclusions: Tropheryma whipplei infection should be considered in inflammatory rheumatic disease patients with extra-articular manifestations, elevated C-reactive protein, and/or hypoalbuminemia before disease-modifying antirheumatic drugs initiation or in inflammatory rheumatic disease patients with an inadequate response to one or more disease-modifying antirheumatic drugs. Positive results of screening and diagnostic tests for Tropheryma whipplei infection involve antibiotic treatment, which is associated with complete recovery of Tropheryma whipplei infection and rapid remission of inflammatory rheumatic disease, allowing disease-modifying antirheumatic drugs and glucocorticoid discontinuation. (c) 2023 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association